Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer
Purpose of reviewThe treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly in the setting of BCG-unresponsive disease, remain limited. We provide updates on recent, promising trials for high-risk NMIBC and newly FDA approved therapies.Recent findingsSeveral therapi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1519428/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850189822939889664 |
|---|---|
| author | Brett Wiesen Paige Hargis Hunter Flores Janet Kukreja |
| author_facet | Brett Wiesen Paige Hargis Hunter Flores Janet Kukreja |
| author_sort | Brett Wiesen |
| collection | DOAJ |
| description | Purpose of reviewThe treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly in the setting of BCG-unresponsive disease, remain limited. We provide updates on recent, promising trials for high-risk NMIBC and newly FDA approved therapies.Recent findingsSeveral therapies with diverse mechanisms of action have shown favorable results in both BCG-naïve and BCG-unresponsive settings for NMIBC. These treatments include intravenous and intravesical immunotherapies, viral- and bacterial-based intravesical therapies, combination intravesical chemotherapy regimens, and novel methods of intravesical chemotherapy administration. Overall, the efficacy and tolerability of these emerging treatments for NMIBC appear promising, offering potential alternatives to radical cystectomy. There have also been recent FDA approvals for novel combination therapy for NMIBC which have been detailed below.SummaryAs the landscape of managing BCG-unresponsive disease evolves, clinical trials will continue to expand the treatment options available for NMIBC. |
| format | Article |
| id | doaj-art-7390e5008efa4f198fe2afe5dcc34de5 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-7390e5008efa4f198fe2afe5dcc34de52025-08-20T02:15:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15194281519428Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancerBrett WiesenPaige HargisHunter FloresJanet KukrejaPurpose of reviewThe treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly in the setting of BCG-unresponsive disease, remain limited. We provide updates on recent, promising trials for high-risk NMIBC and newly FDA approved therapies.Recent findingsSeveral therapies with diverse mechanisms of action have shown favorable results in both BCG-naïve and BCG-unresponsive settings for NMIBC. These treatments include intravenous and intravesical immunotherapies, viral- and bacterial-based intravesical therapies, combination intravesical chemotherapy regimens, and novel methods of intravesical chemotherapy administration. Overall, the efficacy and tolerability of these emerging treatments for NMIBC appear promising, offering potential alternatives to radical cystectomy. There have also been recent FDA approvals for novel combination therapy for NMIBC which have been detailed below.SummaryAs the landscape of managing BCG-unresponsive disease evolves, clinical trials will continue to expand the treatment options available for NMIBC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1519428/fullnon muscle invasive bladder cancernovel therapiesclinical trialsreviewBCG (Bacille Calmette-Guérin) |
| spellingShingle | Brett Wiesen Paige Hargis Hunter Flores Janet Kukreja Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer Frontiers in Oncology non muscle invasive bladder cancer novel therapies clinical trials review BCG (Bacille Calmette-Guérin) |
| title | Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer |
| title_full | Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer |
| title_fullStr | Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer |
| title_full_unstemmed | Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer |
| title_short | Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer |
| title_sort | updated review on novel therapies and ongoing clinical trials for high risk non muscle invasive bladder cancer |
| topic | non muscle invasive bladder cancer novel therapies clinical trials review BCG (Bacille Calmette-Guérin) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1519428/full |
| work_keys_str_mv | AT brettwiesen updatedreviewonnoveltherapiesandongoingclinicaltrialsforhighrisknonmuscleinvasivebladdercancer AT paigehargis updatedreviewonnoveltherapiesandongoingclinicaltrialsforhighrisknonmuscleinvasivebladdercancer AT hunterflores updatedreviewonnoveltherapiesandongoingclinicaltrialsforhighrisknonmuscleinvasivebladdercancer AT janetkukreja updatedreviewonnoveltherapiesandongoingclinicaltrialsforhighrisknonmuscleinvasivebladdercancer |